Poolbeg Pharma (LON:POLB – Get Free Report)‘s stock had its “house stock” rating reiterated by equities research analysts at Shore Capital Group in a report issued on Tuesday,London Stock Exchange reports.
Poolbeg Pharma Stock Performance
POLB stock opened at GBX 7.90 on Tuesday. The firm has a 50-day simple moving average of GBX 5.34 and a two-hundred day simple moving average of GBX 4.64. The firm has a market cap of £55.70 million, a price-to-earnings ratio of -8.40 and a beta of 1.82. Poolbeg Pharma has a one year low of GBX 2.50 and a one year high of GBX 9.
Poolbeg Pharma (LON:POLB – Get Free Report) last issued its quarterly earnings results on Tuesday, April 28th. The company reported GBX (0.94) earnings per share for the quarter. As a group, equities analysts predict that Poolbeg Pharma will post -0.68 earnings per share for the current fiscal year.
About Poolbeg Pharma
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.
See Also
- Five stocks we like better than Poolbeg Pharma
- Can D-Wave Hold Its Own Against 2 Fast-Growing Rivals?
- 3 AI Stocks With Moats That Could Outlast Summer Volatility
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
